| Name | Title | Contact Details |
|---|
Genetic Technologies, Inc. is an independent, full service and multi-accredited DNA forensic science company focusing primarily on the testing and evaluation of forensic evidence as it relates to human identification. Established in 1998, Genetic Technologies, Inc. serves a rapidly growing nationwide and worldwide customer base of private citizens, investigators, law enforcement agencies, public defenders, criminal defense attorneys, and prosecutors. We offer our clients access to a broad range of forensic biology technologies—specializing in DNA analysis, (Autosomal and Y-STRs), touch DNA (Low Copy Analysis), Crime Scene Investigation (CSI), serology, and expert witness & consulting services for civil investigations / criminal prosecution & defense. Our forensic division has played a pivotal role in a hundreds of high profile criminal cases with our civil and relatedness divisions assisting clients in thousands of immigration / relatedness DNA tests including a wide spectrum of infidelity scenarios. Our seasoned staff of expert scientists utilizes the most advanced methodologies available to detect and test DNA from many sources. We offer fast, accurate and personalized service for each of our customers, including consulting and expert witness services in conjunction with forensic testing. Genetic Technologies, Inc. is a leader in the Forensic Science and Human Identification Industry and provides specialized software to the eDNA Consortium. eDNA is a software developed by Genetic Technologies, Inc. which is used by many facilities in the Human Identification Industry.
Hallmark Health System is a Melrose, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Consult-Pro is a East York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radiancy, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Orangeburg, NY. To find more information about Radiancy, Inc., please visit www.radiancy.com
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.